Last updated on September 2018

A Study to Assess Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Brief description of study

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia.

Clinical Study Identifier: NCT03275454

Contact Investigators or Research Sites near you

Start Over

Bioverativ - a Sanofi company

Georgetown Lombardi Comprehensive Cancer Center
Georgetown, WA United States
  Connect »